文献速递类风湿关节炎

PERFECTRA:一项在csDMARDs治疗失败的活动性类风湿关节炎患者中比较巴瑞替尼与TNF抑制剂达标治疗策略的实用性、多中心、真实世界研究

PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
PubMed 文献 · RMD Open · 2024-05-30

PERFECTRA研究将b/tsDMARD初治、病程≤5年的类风湿关节炎患者在csDMARD失败后随机分配至TNF抑制剂或巴瑞替尼达标治疗策略,随访48周。巴瑞替尼策略在第12周ACR50应答上既非劣效又优效(42% vs 20%),且75%患者达到DAS28-CRP<2.6(TNFi组46%)。

要点

  • 巴瑞替尼策略第12周ACR50应答42%,TNFi组20%,非劣效且优效。
  • 第12周DAS28-CRP<2.6比例巴瑞替尼组75%,TNFi组46%。
  • 次要结局全程巴瑞替尼策略不劣于或优于TNFi策略。

核心结论

  • 在达标治疗背景下,csDMARDs治疗失败的RA患者可考虑JAK抑制剂或bDMARDs(临床实践中主要为TNFi)两种主要策略。
  • PERFECTRA研究提示起始巴瑞替尼在第12周应答上优于TNFi,并在整个研究期间改善所有研究的临床指标和PROMs。

研究设计与样本

  • 实用性、多中心、真实世界随机研究,纳入b/tsDMARD初治、病程≤5年、无b/tsDMARD禁忌证的RA患者,csDMARD未达标后随机分配至TNFi或巴瑞替尼达标治疗策略。
  • 每12周评估临床和患者报告结局指标(PROMs),持续48周;主要终点为第12周ACR50应答的非劣效性,若证实非劣效则检验优效性。
  • 共199例患者(TNFi组n=102;巴瑞替尼组n=97),两组基线相似。

主要发现

  • 第12周ACR50应答率巴瑞替尼组42% vs TNFi组20%,巴瑞替尼既非劣效又优效。
  • 第12周DAS28-CRP<2.6比例巴瑞替尼组75% vs TNFi组46%。
  • 研究全程次要结局中,巴瑞替尼策略显示与TNFi策略相当或更优的结局。
  • 虽未以安全性为效能设计,但在这相对较小的患者群体中未见非预期安全信号。

临床怎么用

  • 作者认为,在达标治疗背景下,csDMARDs失败的RA患者有JAK抑制剂与bDMARDs(临床实践中主要为TNFi)两种主要策略可考虑。
  • 作者认为,起始巴瑞替尼在第12周应答上优于TNFi,并在整个研究期间改善所有研究的临床指标和PROMs。

局限性

  • 研究未以安全性为效能设计,安全性分析基于相对较小的患者群体,未见非预期安全信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effectiveness of a strategy administering baricitinib versus one using TNF-inhibitors (TNFi) in patients with rheumatoid arthritis (RA) after conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) failure in a real-life treat-to-target (T2T) setting. METHODS: Patients with biological and targeted synthetic DMARD (b/tsDMARD) naïve RA with disease duration ≤5 years without contraindications to b/tsDMARD were randomised to either TNFi or baricitinib when csDMARD failed to achieve disease control in a T2T setting. Changes in clinical and patient-reported outcome measures (PROMs) were assessed at 12-week intervals for 48 weeks. The primary endpoint was non-inferiority, with testing for superiority if non-inferiority is demonstrated, of baricitinib strategy in the number of patients achieving American College of Rheumatology 50 (ACR50) response at 12 weeks. Secondary endpoints included 28-joint count Disease Activity Score with C reactive protein (DAS28-CRP) <2.6, changes in PROMs and radiographic progression. RESULTS: A total of 199 patients (TNFi, n=102; baricitinib, n=97) were studied. Both study groups were similar. Baricitinib was both non-inferior and superior in achieving ACR50 response at week 12 (42% vs 20%). Moreover, 75% of baricitinib patients achieved DAS28-CRP <2.6 at week 12 compared with 46% of TNFi patients. On secondary outcomes throughout the duration of the study, the baricitinib strategy demonstrated comparable or better outcomes than TNFi strategy. Although not powered for safety, no unexpected safety signals were seen in this relatively small group of patients. CONCLUSION: Up to present, in a T2T setting, patients with RA failing csDMARDs have two main strategies to consider, Janus Kinases inhibitor versus bDMARDs (in clinical practice, predominantly TNFi). The PERFECTRA study suggested that starting with baricitinib was superior over TNFi in achieving response at 12 weeks and resulted in improved outcomes across all studied clinical measures and PROMs throughout the study duration in these patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van de Laar CJ, Oude Voshaar MAH, Ten Klooster P, et al. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open. 2024. PMID: 38816210. doi:10.1136/rmdopen-2024-004291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。